Instituto de Diabetes, Obesidad y Nutrición S.C.

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease3 trials
• Type 2 diabetes3 trials
• Fatty liver disease (MASLD/MASH)2 trials
• Obesity2 trials
• High blood pressure1 trial
• Liver cirrhosis1 trial
• Type 1 diabetes1 trial

Phase

• Phase 36 trials
• Phase 21 trial

Status

• Recruiting4 trials
• Completed2 trials
• Active, not recruiting1 trial

Lead sponsor

• Boehringer Ingelheim5 trials
• Inversago Pharma Inc.1 trial
• Pfizer1 trial

Running trials

• Recruiting

  A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

  NCT07595549· Phase 3· Pfizer· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)2 recruiting
• Type 2 diabetes2 recruiting
• High blood pressure1 recruiting
• Liver cirrhosis1 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

  NCT05514548· Phase 2· Inversago Pharma Inc.· Source